請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70083
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 邱麗珠(Lih-Chu Chiou) | |
dc.contributor.author | Guan-Ling Lu | en |
dc.contributor.author | 盧冠伶 | zh_TW |
dc.date.accessioned | 2021-06-17T03:42:35Z | - |
dc.date.available | 2019-02-22 | |
dc.date.copyright | 2018-02-22 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-02-06 | |
dc.identifier.citation | Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L (2007) Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450:420-424.
Akbari E, Naghdi N, Motamedi F (2006) Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. Behavioural brain research 173:47-52. Akbari E, Naghdi N, Motamedi F (2007) The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. Peptides 28:650-656. Akbari E, Motamedi F, Naghdi N, Noorbakhshnia M (2008) The effect of antagonization of orexin 1 receptors in CA1 and dentate gyrus regions on memory processing in passive avoidance task. Behavioural brain research 187:172-177. Akbari E, Motamedi F, Davoodi FG, Noorbakhshnia M, Ghanbarian E (2011) Orexin-1 receptor mediates long-term potentiation in the dentate gyrus area of freely moving rats. Behavioural brain research 216:375-380. Alijanpour S, Tirgar F, Zarrindast MR (2016) Role of dorsal hippocampal orexin-1 receptors in memory restoration induced by morphine sensitization phenomenon. Neuroscience 312:215-226. Ammoun S, Holmqvist T, Shariatmadari R, Oonk HB, Detheux M, Parmentier M, Akerman KE, Kukkonen JP (2003) Distinct recognition of OX1 and OX2 receptors by orexin peptides. J Pharmacol Exp Ther 305:507-514. Aou S, Li XL, Li AJ, Oomura Y, Shiraishi T, Sasaki K, Imamura T, Wayner MJ (2003) Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral long-term potentiation in rats. Neuroscience 119:1221-1228. Arai A, Black J, Lynch G (1994) Origins of the variations in long-term potentiation between synapses in the basal versus apical dendrites of hippocampal neurons. Hippocampus 4:1-9. Aston-Jones G, Smith RJ, Moorman DE, Richardson KA (2009) Role of lateral hypothalamic orexin neurons in reward processing and addiction. Neuropharmacology 56 Suppl 1:112-121. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, Richardson KA (2010) Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain research 1314:74-90. Azhdari Zarmehri H, Semnanian S, Fathollahi Y, Erami E, Khakpay R, Azizi H, Rohampour K (2011) Intra-periaqueductal gray matter microinjection of orexin-A decreases formalin-induced nociceptive behaviors in adult male rats. The journal of pain : official journal of the American Pain Society 12:280-287. Balestrino M, Aitken PG, Somjen GG (1986) The effects of moderate changes of extracellular K+ and Ca2+ on synaptic and neural function in the CA1 region of the hippocampal slice. Brain research 377:229-239. Bashir ZI, Collingridge GL (1994) An investigation of depotentiation of long-term potentiation in the CA1 region of the hippocampus. Exp Brain Res 100:437-443. Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A, Porter RA, Upton N, Hunter AJ, Parsons AA (2001) Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92:81-90. Bliss TV, Collingridge GL (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39. Bonnavion P, Mickelsen LE, Fujita A, de Lecea L, Jackson AC (2016) Hubs and spokes of the lateral hypothalamus: cell types, circuits and behaviour. The Journal of physiology. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49:589-601. Boss C, Roch C (2015) Recent trends in orexin research-2010 to 2015. Bioorg Med Chem Lett 25:2875-2887. Brodnik ZD, Bernstein DL, Prince CD, Espana RA (2015) Hypocretin receptor 1 blockade preferentially reduces high effort responding for cocaine without promoting sleep. Behavioural brain research 291:377-384. Burdakov D, Jensen LT, Alexopoulos H, Williams RH, Fearon IM, O'Kelly I, Gerasimenko O, Fugger L, Verkhratsky A (2006) Tandem-pore K+ channels mediate inhibition of orexin neurons by glucose. Neuron 50:711-722. Burgess CR, Oishi Y, Mochizuki T, Peever JH, Scammell TE (2013) Amygdala lesions reduce cataplexy in orexin knock-out mice. J Neurosci 33:9734-9742. Cadoni C (2016) Fischer 344 and Lewis Rat Strains as a Model of Genetic Vulnerability to Drug Addiction. Frontiers in neuroscience 10:13. Capocchi G, Zampolini M, Larson J (1992) Theta burst stimulation is optimal for induction of LTP at both apical and basal dendritic synapses on hippocampal CA1 neurons. Brain research 591:332-336. Centonze D, Costa C, Rossi S, Prosperetti C, Pisani A, Usiello A, Bernardi G, Mercuri NB, Calabresi P (2006) Chronic cocaine prevents depotentiation at corticostriatal synapses. Biol Psychiatry 60:436-443. Cervo L, Samanin R (1995) Effects of dopaminergic and glutamatergic receptor antagonists on the acquisition and expression of cocaine conditioning place preference. Brain research 673:242-250. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437-451. Chen J, Randeva HS (2010) Genomic organization and regulation of the human orexin (hypocretin) receptor 2 gene: identification of alternative promoters. The Biochemical journal 427:377-390. Chen XY, Chen L, Du YF (2017) Orexin-A increases the firing activity of hippocampal CA1 neurons through orexin-1 receptors. Journal of neuroscience research 95:1415-1426. Chieffi S, Carotenuto M, Monda V, Valenzano A, Villano I, Precenzano F, Tafuri D, Salerno M, Filippi N, Nuccio F, Ruberto M, De Luca V, Cipolloni L, Cibelli G, Mollica MP, Iacono D, Nigro E, Monda M, Messina G, Messina A (2017) Orexin System: The Key for a Healthy Life. Frontiers in physiology 8:357. Chiou LC, Lee HJ, Ho YC, Chen SP, Liao YY, Ma CH, Fan PC, Fuh JL, Wang SJ (2010) Orexins/hypocretins: pain regulation and cellular actions. Curr Pharm Des 16:3089-3100. Chung HJ, Ge WP, Qian X, Wiser O, Jan YN, Jan LY (2009) G protein-activated inwardly rectifying potassium channels mediate depotentiation of long-term potentiation. Proceedings of the National Academy of Sciences of the United States of America 106:635-640. Cluderay JE, Harrison DC, Hervieu GJ (2002) Protein distribution of the orexin-2 receptor in the rat central nervous system. Regulatory peptides 104:131-144. Collingridge GL, Peineau S, Howland JG, Wang YT (2010) Long-term depression in the CNS. Nature reviews Neuroscience 11:459-473. Dang R, Chen Q, Song J, He C, Zhang J, Xia J, Hu Z (2018) Orexin knockout mice exhibit impaired spatial working memory. Neuroscience letters 668:92-97. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS, 2nd, Frankel WN, van den Pol AN, Bloom FE, Gautvik KM, Sutcliffe JG (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proceedings of the National Academy of Sciences of the United States of America 95:322-327. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences of the United States of America 85:5274-5278. Dietrich H, Jenck F (2010) Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) 212:145-154. Dohi K, Nishino S, Nakamachi T, Ohtaki H, Morikawa K, Takeda T, Shioda S, Aruga T (2006) CSF orexin A concentrations and expressions of the orexin-1 receptor in rat hippocampus after cardiac arrest. Neuropeptides 40:245-250. El-Armouche A, Bednorz A, Pamminger T, Ditz D, Didie M, Dobrev D, Eschenhagen T (2006) Role of calcineurin and protein phosphatase-2A in the regulation of phosphatase inhibitor-1 in cardiac myocytes. Biochemical and biophysical research communications 346:700-706. Farahmandfar M, Kadivar M, Rastipisheh S (2016) Blockade of dorsal hippocampal orexin-1 receptors impaired morphine-induced state-dependent learning. Neuropeptides 60:13-19. Ferbinteanu J, McDonald RJ (2001) Dorsal/ventral hippocampus, fornix, and conditioned place preference. Hippocampus 11:187-200. Flores A, Valls-Comamala V, Costa G, Saravia R, Maldonado R, Berrendero F (2014) The hypocretin/orexin system mediates the extinction of fear memories. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 39:2732-2741. Funato H (2015) Orexin and Metabolism. In: Orexin and Sleep: Molecular, Functional and Clinical Aspects (Sakurai T, Pandi-Perumal SR, Monti JM, eds), pp 363-380. Cham: Springer International Publishing. Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, Yanagisawa M (2009) Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell metabolism 9:64-76. Gautvik KM, de Lecea L, Gautvik VT, Danielson PE, Tranque P, Dopazo A, Bloom FE, Sutcliffe JG (1996) Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. Proceedings of the National Academy of Sciences of the United States of America 93:8733-8738. Gentile TA, Simmons SJ, Barker DJ, Shaw JK, Espana RA, Muschamp JW (2017) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addiction biology. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, DiLeone RJ (2003) Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23:3106-3111. Goodrick S (2015) Orexin or hypocretin? The Lancet Neurology 14:249. Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ (2012) International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology. Pharmacological reviews 64:389-420. Grover LM, Kim E, Cooke JD, Holmes WR (2009) LTP in hippocampal area CA1 is induced by burst stimulation over a broad frequency range centered around delta. Learn Mem 16:69-81. Gruart A, Munoz MD, Delgado-Garcia JM (2006) Involvement of the CA3-CA1 synapse in the acquisition of associative learning in behaving mice. J Neurosci 26:1077-1087. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345-354. Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437:556-559. Harris GC, Wimmer M, Randall-Thompson JF, Aston-Jones G (2007) Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. Behavioural brain research 183:43-51. Haynes AC, Jackson B, Overend P, Buckingham RE, Wilson S, Tadayyon M, Arch JR (1999) Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 20:1099-1105. He M, Shippenberg TS (2000) Strain differences in basal and cocaine-evoked dopamine dynamics in mouse striatum. The Journal of pharmacology and experimental therapeutics 293:121-127. Hnasko TS, Sotak BN, Palmiter RD (2007) Cocaine-conditioned place preference by dopamine-deficient mice is mediated by serotonin. J Neurosci 27:12484-12488. Ho YC, Lee HJ, Tung LW, Liao YY, Fu SY, Teng SF, Liao HT, Mackie K, Chiou LC (2011) Activation of orexin 1 receptors in the periaqueductal gray of male rats leads to antinociception via retrograde endocannabinoid (2-arachidonoylglycerol)-induced disinhibition. J Neurosci 31:14600-14610. Holmqvist T, Akerman KE, Kukkonen JP (2002) Orexin signaling in recombinant neuron-like cells. FEBS letters 526:11-14. Hong I, Song B, Lee S, Kim J, Choi S (2009) Extinction of cued fear memory involves a distinct form of depotentiation at cortical input synapses onto the lateral amygdala. The European journal of neuroscience 30:2089-2099. Hongpaisan J, Winters CA, Andrews SB (2004) Strong calcium entry activates mitochondrial superoxide generation, upregulating kinase signaling in hippocampal neurons. J Neurosci 24:10878-10887. Huang CC, Liang YC, Hsu KS (1999) A role for extracellular adenosine in time-dependent reversal of long-term potentiation by low-frequency stimulation at hippocampal CA1 synapses. J Neurosci 19:9728-9738. Huang CC, Liang YC, Hsu KS (2001a) Characterization of the mechanism underlying the reversal of long term potentiation by low frequency stimulation at hippocampal CA1 synapses. The Journal of biological chemistry 276:48108-48117. Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T, Urade Y, Hayaishi O (2001b) Arousal effect of orexin A depends on activation of the histaminergic system. Proceedings of the National Academy of Sciences of the United States of America 98:9965-9970. Huston JP, Silva MA, Topic B, Muller CP (2013) What's conditioned in conditioned place preference? Trends in pharmacological sciences 34:162-166. Hwang L-L, Wang C-H, Li T-L, Chang S-D, Lin L-C, Chen C-P, Chen C-T, Liang K-C, Ho I-K, Yang W-S, Chiou L-C (2010) Sex Differences in High-fat Diet-induced Obesity, Metabolic Alterations and Learning, and Synaptic Plasticity Deficits in Mice. Obesity 18:463-469. Hyttel J (1983) SCH 23390 - the first selective dopamine D-1 antagonist. European journal of pharmacology 91:153-154. Inutsuka A, Inui A, Tabuchi S, Tsunematsu T, Lazarus M, Yamanaka A (2014) Concurrent and robust regulation of feeding behaviors and metabolism by orexin neurons. Neuropharmacology 85:451-460. Jaeger LB, Farr SA, Banks WA, Morley JE (2002) Effects of orexin-A on memory processing. Peptides 23:1683-1688. James MH, Mahler SV, Moorman DE, Aston-Jones G (2017) A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Current topics in behavioral neurosciences 33:247-281. Johnson PL, Molosh A, Fitz SD, Truitt WA, Shekhar A (2012) Orexin, stress, and anxiety/panic states. Progress in brain research 198:133-161. Jouvenceau A, Hedou G, Potier B, Kollen M, Dutar P, Mansuy IM (2006) Partial inhibition of PP1 alters bidirectional synaptic plasticity in the hippocampus. The European journal of neuroscience 24:564-572. Karnani MM, Apergis-Schoute J, Adamantidis A, Jensen LT, de Lecea L, Fugger L, Burdakov D (2011) Activation of central orexin/hypocretin neurons by dietary amino acids. Neuron 72:616-629. Karteris E, Machado RJ, Chen J, Zervou S, Hillhouse EW, Randeva HS (2005) Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. American journal of physiology Endocrinology and metabolism 288:E1089-1100. Kemp N, McQueen J, Faulkes S, Bashir ZI (2000) Different forms of LTD in the CA1 region of the hippocampus: role of age and stimulus protocol. The European journal of neuroscience 12:360-366. Kotz CM, Teske JA, Levine JA, Wang C (2002) Feeding and activity induced by orexin A in the lateral hypothalamus in rats. Regulatory peptides 104:27-32. Kukkonen JP (2016) OX2 orexin/hypocretin receptor signal transduction in recombinant Chinese hamster ovary cells. Cellular signalling 28:51-60. Kukkonen JP, Leonard CS (2014) Orexin/hypocretin receptor signalling cascades. Br J Pharmacol 171:314-331. Kulla A, Manahan-Vaughan D (2000) Depotentiation in the dentate gyrus of freely moving rats is modulated by D1/D5 dopamine receptors. Cerebral cortex 10:614-620. Lee HJ, Chang LY, Ho YC, Teng SF, Hwang LL, Mackie K, Chiou LC (2016) Stress induces analgesia via orexin 1 receptor-initiated endocannabinoid/CB1 signaling in the mouse periaqueductal gray. Neuropharmacology 105:577-586. Li J, Hu Z, de Lecea L (2014) The hypocretins/orexins: integrators of multiple physiological functions. Br J Pharmacol 171:332-350. Li SB, Giardino WJ, de Lecea L (2017) Hypocretins and Arousal. Current topics in behavioral neurosciences 33:93-104. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365-376. Linehan V, Trask RB, Briggs C, Rowe TM, Hirasawa M (2015) Concentration-dependent activation of dopamine receptors differentially modulates GABA release onto orexin neurons. The European journal of neuroscience 42:1976-1983. Lu GL, Lee CH, Chiou LC (2016) Orexin A induces bidirectional modulation of synaptic plasticity: Inhibiting long-term potentiation and preventing depotentiation. Neuropharmacology 107:168-180. Lu GL, Yau HJ, Chiou LC (2017) Conditioned place preference training prevents hippocampal depotentiation in an orexin-dependent manner. Journal of biomedical science 24:69. Lu XY, Bagnol D, Burke S, Akil H, Watson SJ (2000) Differential distribution and regulation of OX1 and OX2 orexin/hypocretin receptor messenger RNA in the brain upon fasting. Hormones and behavior 37:335-344. Lund PE, Shariatmadari R, Uustare A, Detheux M, Parmentier M, Kukkonen JP, Akerman KE (2000) The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C. J Biol Chem 275:30806-30812. Mahler SV, Moorman DE, Smith RJ, James MH, Aston-Jones G (2014) Motivational activation: a unifying hypothesis of orexin/hypocretin function. Nature neuroscience 17:1298-1303. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. The Journal of comparative neurology 435:6-25. Mavanji V, Butterick TA, Duffy CM, Nixon JP, Billington CJ, Kotz CM (2017) Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice. Neurobiology of learning and memory 146:21-30. Meyers RA, Zavala AR, Speer CM, Neisewander JL (2006) Dorsal hippocampus inhibition disrupts acquisition and expression, but not consolidation, of cocaine conditioned place preference. Behavioral neuroscience 120:401-412. Miguens M, Coria SM, Higuera-Matas A, Fole A, Ambrosio E, Del Olmo N (2011) Depotentiation of hippocampal long-term potentiation depends on genetic background and is modulated by cocaine self-administration. Neuroscience 187:36-42. Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, Kamenecka TM, Borgland SL, Kenny PJ, Carlezon WA, Jr. (2014) Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proceedings of the National Academy of Sciences of the United States of America 111:E1648-1655. Nambu T, Sakurai T, Mizukami K, Hosoya Y, Yanagisawa M, Goto K (1999) Distribution of orexin neurons in the adult rat brain. Brain research 827:243-260. Nestler EJ (2013) Cellular basis of memory for addiction. Dialogues in clinical neuroscience 15:431-443. Nishino S, Mignot E (1997) Pharmacological aspects of human and canine narcolepsy. Progress in neurobiology 52:27-78. Norman JL, Anderson SL (2016) Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nature and science of sleep 8:239-247. Oka H, Shimono K, Ogawa R, Sugihara H, Taketani M (1999) A new planar multielectrode array for extracellular recording: application to hippocampal acute slice. Journal of Neuroscience Methods 93:61-67. Otmakhova NA, Lisman JE (1998) D1/D5 dopamine receptors inhibit depotentiation at CA1 synapses via cAMP-dependent mechanism. J Neurosci 18:1270-1279. Perin M, Longordo F, Massonnet C, Welker E, Luthi A (2014) Diurnal inhibition of NMDA-EPSCs at rat hippocampal mossy fibre synapses through orexin-2 receptors. The Journal of physiology 592:4277-4295. Petersen A, Gil J, Maat-Schieman ML, Bjorkqvist M, Tanila H, Araujo IM, Smith R, Popovic N, Wierup N, Norlen P, Li JY, Roos RA, Sundler F, Mulder H, Brundin P (2005) Orexin loss in Huntington's disease. Hum Mol Genet 14:39-47. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996-10015. Peyron C et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature medicine 6:991-997. Prakash S, Ambrosio E, Alguacil LF, Del Olmo N (2009) Genetic differences in hippocampal synaptic plasticity. Neuroscience 161:342-346. Prescott IA, Liu LD, Dostrovsky JO, Hodaie M, Lozano AM, Hutchison WD (2014) Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia. Neurobiol Dis 71:24-33. Pruitt DL, Bolanos CA, McDougall SA (1995) Effects of dopamine D1 and D2 receptor antagonists on cocaine-induced place preference conditioning in preweanling rats. European journal of pharmacology 283:125-131. Putula J, Pihlajamaa T, Kukkonen JP (2014) Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br J Pharmacol 171:5816-5828. Qi Y, Hu NW, Rowan MJ (2013) Switching off LTP: mGlu and NMDA receptor-dependent novelty exploration-induced depotentiation in the rat hippocampus. Cerebral cortex 23:932-939. Randeva HS, Karteris E, Grammatopoulos D, Hillhouse EW (2001) Expression of orexin-A and functional orexin type 2 receptors in the human adult adrenals: implications for adrenal function and energy homeostasis. The Journal of clinical endocrinology and metabolism 86:4808-4813. Rao Y, Mineur YS, Gan G, Wang AH, Liu ZW, Wu X, Suyama S, de Lecea L, Horvath TL, Picciotto MR, Gao XB (2013) Repeated in vivo exposure of cocaine induces long-lasting synaptic plasticity in hypocretin/orexin-producing neurons in the lateral hypothalamus in mice. The Journal of physiology 591:1951-1966. Rashidy-Pour A, Moradi M, Fatahi Z, Haghparast A, Haghparast A (2015) Role of intra-hippocampal orexin 1 and orexin 2 receptors in conditioned place preference induced by chemical stimulation of the lateral hypothalamus. Behavioural brain research 279:106-111. Razavi BM, Hosseinzadeh H (2017) A review of the role of orexin system in pain modulation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 90:187-193. Riahi E, Arezoomandan R, Fatahi Z, Haghparast A (2015) The electrical activity of hippocampal pyramidal neuron is subjected to descending control by the brain orexin/hypocretin system. Neurobiology of learning and memory 119:93-101. Sakurai T (2007) The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nature reviews Neuroscience 8:171-181. Sakurai T (2014) The role of orexin in motivated behaviours. Nature reviews Neuroscience 15:719-731. Sakurai T et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585. Sartor GC, Aston-Jones GS (2012) A septal-hypothalamic pathway drives orexin neurons, which is necessary for conditioned cocaine preference. J Neurosci 32:4623-4631. Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T (2011) Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. PloS one 6:e20360. Selbach O, Bohla C, Barbara A, Doreulee N, Eriksson KS, Sergeeva OA, Haas HL (2010) Orexins/hypocretins control bistability of hippocampal long-term synaptic plasticity through co-activation of multiple kinases. Acta physiologica (Oxford, England) 198:277-285. Selbach O, Doreulee N, Bohla C, Eriksson KS, Sergeeva OA, Poelchen W, Brown RE, Haas HL (2004) Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. Neuroscience 127:519-528. Sharf R, Guarnieri DJ, Taylor JR, DiLeone RJ (2010) Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain research 1317:24-32. Steiner MA, Lecourt H, Jenck F (2013) The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. The international journal of neuropsychopharmacology 16:417-432. Telegdy G, Adamik A (2002) The action of orexin A on passive avoidance learning. Involvement of transmitters. Regulatory peptides 104:105-110. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469-474. Thompson MD, Sakurai T, Rainero I, Maj MC, Kukkonen JP (2017) Orexin Receptor Multimerization versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics. Pharmaceuticals 10. Thorpe AJ, Teske JA, Kotz CM (2005) Orexin A-induced feeding is augmented by caloric challenge. American journal of physiology Regulatory, integrative and comparative physiology 289:R367-R372. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM (1998) Distribution of orexin receptor mRNA in the rat brain. FEBS letters 438:71-75. Tsujino N, Sakurai T (2013) Role of orexin in modulating arousal, feeding, and motivation. Frontiers in behavioral neuroscience 7:28. Tsuneki H, Sasaoka T, Sakurai T (2016) Sleep Control, GPCRs, and Glucose Metabolism. Trends in endocrinology and metabolism: TEM 27:633-642. Tung LW, Lu GL, Lee YH, Yu L, Lee HJ, Leishman E, Bradshaw H, Hwang LL, Hung MS, Mackie K, Zimmer A, Chiou LC (2016) Orexins contribute to restraint stress-induced cocaine relapse by endocannabinoid-mediated disinhibition of dopaminergic neurons. Nature communications 7:12199. Tzschentke TM (1998) Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Progress in neurobiology 56:613-672. Tzschentke TM (2007) Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addiction biology 12:227-462. Valdivia S, Patrone A, Reynaldo M, Perello M (2014) Acute high fat diet consumption activates the mesolimbic circuit and requires orexin signaling in a mouse model. PloS one 9:e87478. Wagner JJ, Alger BE (1996) Homosynaptic LTD and depotentiation: do they differ in name only? Hippocampus 6:24-29. Wayner MJ, Armstrong DL, Phelix CF, Oomura Y (2004) Orexin-A (Hypocretin-1) and leptin enhance LTP in the dentate gyrus of rats in vivo. Peptides 25:991-996. Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, Uslaner JM, Uebele VN, Doran SM, Fox SV, Garson SL, Gotter AL, Levine DM, Roecker AJ, Coleman PJ, Koblan KS, Renger JJ (2010) Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. Neuropharmacology 58:185-194. Woldan-Tambor A, Bieganska K, Wiktorowska-Owczarek A, Zawilska JB (2011) Activation of orexin/hypocretin type 1 receptors stimulates cAMP synthesis in primary cultures of rat astrocytes. Pharmacological reports : PR 63:717-723. Yang B, Samson WK, Ferguson AV (2003) Excitatory effects of orexin-A on nucleus tractus solitarius neurons are mediated by phospholipase C and protein kinase C. J Neurosci 23:6215-6222. Yang L, Zou B, Xiong X, Pascual C, Xie J, Malik A, Xie J, Sakurai T, Xie XS (2013) Hypocretin/orexin neurons contribute to hippocampus-dependent social memory and synaptic plasticity in mice. J Neurosci 33:5275-5284. Zhao X, Zhang R, Tang S, Ren Y, Yang W, Liu X, Tang J (2014) Orexin-A-induced ERK1/2 activation reverses impaired spatial learning and memory in pentylenetetrazol-kindled rats via OX1R-mediated hippocampal neurogenesis. Peptides 54:140-147. Zho WM, You JL, Huang CC, Hsu KS (2002) The group I metabotropic glutamate receptor agonist (S)-3,5-dihydroxyphenylglycine induces a novel form of depotentiation in the CA1 region of the hippocampus. J Neurosci 22:8838-8849. Zhou Q, Poo MM (2004) Reversal and consolidation of activity-induced synaptic modifications. Trends in neurosciences 27:378-383. Zhu Y, Miwa Y, Yamanaka A, Yada T, Shibahara M, Abe Y, Sakurai T, Goto K (2003) Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. Journal of pharmacological sciences 92:259-266. Zucker RS, Regehr WG (2002) Short-term synaptic plasticity. Annual review of physiology 64:355-405. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70083 | - |
dc.description.abstract | 食慾素系統包括兩種肽-食慾素A與B,以及兩種受體-食慾素受體1與2。食慾素系統被認為參與了學習與記憶的調節,但是對於其調控海馬迴路突觸可塑性仍有許多爭議。我們使用胞外電生理紀錄在小鼠海馬迴腦片Schaffer Collateral-CA1突觸測量場興奮突觸後電位 (fEPSPs) 來觀察突觸可塑性。我們同時也使用制約場地偏好 [conditioned place preference (CPP) task] 反應來觀察海馬迴相關的學習及藥物制約喜好行為。
首先,我們針對食慾素A在小鼠海馬迴腦片Schaffer Collateral-CA1 突觸的兩種場興奮突觸後電位之突觸可塑性,如長期增益 (LTP) 以及去增益 (depotentiation) 的影響加以研究。當外給食慾素A濃度超過30 nM會降低LTP,而此現象可以被食慾素受體1拮抗劑 (SB334867) 而非受體2拮抗劑 (EMPA) 所拮抗。相反地,外給食慾素A在低濃度1 pM的情況下,可以避免去增益 (depotentiation) 的程度,而這種回復突觸增益程度的情況我們稱之為再增益 (re-potentiation)。這種由極低濃度的食慾素A所產生的再增益現象僅發生在給予1赫茲而非2赫茲的低頻刺激中觀察到,而高頻刺激則不限TBS或是僵直性刺激 (tetanic stimulation)。當我們同時給予選擇性的食慾素受體1 (SB334867) 與受體2 (EMPA) 的拮抗劑甚至是雙重食慾素受體拮抗劑 (TCS1102) 都可以顯著地對抗由極低濃度的食慾素A所產生的再增益現象。此外若是事先給予磷脂酶C (phospholipase C, PLC) 或腺苷酸環化酶 (adenylyl cyclase, AC) 及蛋白激酶A (protein kinase A, PKA) 的拮抗劑都可以預防由極低濃度的食慾素A所產生的再增益現象。另外我們使用化學方法產生去增益現象,如NMDA受體與 A1 腺苷受體 (A1-adenosine receptor) 及代謝性谷氨酸受體 [type 1/5 metabotropic glutamate (mGlu1/5) receptors] 的激活劑可以取代低頻刺激來產生去增益現象,且其拮抗劑可對抗低頻刺激所產生的去增益現象,上述的受體激活劑產生的去增益現象並不會受到極低濃度的食慾素A的影響。這個結果暗示我們食慾素A雙向調控海馬迴CA1突觸可塑性,在適當濃度下經由食慾素受體1來抑制長期增益現象,而在極低濃度下藉由食慾素受體1和2及其訊息傳遞磷脂酶C或腺苷酸環化酶及蛋白激酶A來產生再增益現象。 接著我們想要探討極低濃度食慾素A所產生的再增益現象是否具有生理意義。活化多巴胺受體 (D1-like R)曾經被報導可以產生海馬迴突觸的再增益現象,而這種現象與可卡因 (cocaine)制約場地偏好行為有關,因此我們想要檢視是否食慾素所引起的再增益現象也參與在可卡因制約場地偏好行為中。我們將參與可卡因制約場地偏好測試的小鼠取出海馬迴腦片測量突觸可塑性的改變。在產生可卡因場地制約偏好的小鼠上確實如預期觀察到顯著的再增益現象。但是令人吃驚的是給予食鹽水的對照組別,卻同時觀察到具有再增益現象;當我們使用相同的藥物處理時,改用飼養的鼠籠 (home cage) 取代制約場地,則無法觀察到海馬迴腦片中的再增益現象。因此我們推論制約場地的訓練可能會引起海馬迴腦片的再增益現象發生,且此現象與可卡因藥物的給予並不相關。更進一步,我們發現到單純進入制約場地但缺少注射行為的訓練過程,並無法引起海馬迴腦片的再增益現象發生,顯示制約場地訓練引起海馬迴腦片的再增益現象發生是需要配合注射行為的操弄,但是單純的注射操弄並無法引起海馬迴腦片的再增益現象。我們假設此制約場地訓練引起海馬迴腦片的再增益現象與體內極低濃度食慾素的釋出有關,因此在進行制約場地訓練前給予雙重食慾素受體拮抗劑 (TCS1102)可以對抗海馬迴腦片的再增益現象發生。 更進一步的實驗中,我們想要解釋可卡因處理之制約場地偏好改變的小鼠所產生偏好行為與海馬迴腦片的再增益現象是否與體內食慾素的釋出有關。我們發現可卡因制約場地偏好小鼠在給予10或20 mg/kg的可卡因時,會有相同程度的偏好行為與海馬迴腦片的再增益現象。但是當我們在進行制約場地與可卡因 (10 mg/kg) 配對前,也就是獲取狀態 (acquisition phase) 給予雙重食慾素受體拮抗劑 (TCS1102) 可以對抗偏好行為及海馬迴腦片的再增益現象發生,而在較高濃度的可卡因 (20 mg/kg) 配對時,給予雙重食慾素受體拮抗劑 (TCS1102) 並不能夠對抗偏好行為及海馬迴腦片的再增益現象發生。此外我們也發現較高濃度的可卡因 (20 mg/kg) 配對時,需要給予多巴胺受體 (D1-like R) 的拮抗劑來對抗偏好行為及海馬迴腦片的再增益現象發生。 這個結果暗示我們外給食慾素A在小鼠海馬迴腦片Schaffer Collateral-CA1 突觸的突觸可塑性是雙向的,可以抑制長期增益且預防低頻刺激的去增益現象發生;同時我們針對極低濃度食慾素A所產生的再增益現象與1赫茲的低頻刺激有關係,並透過活化食慾素受體1與2,其訊息傳遞路徑為磷脂酶C或腺苷酸環化酶及蛋白激酶A。低頻刺激所誘發產生的去增益現象對於低濃度的食慾素是非常敏感的,當連結到制約場地不同空間情境及制約操作的注射時就可以被釋放而產生再增益現象。另一方面,食慾素調節的海馬迴再增益現象也可以在形成可卡因場地偏好上有貢獻,然而僅限於適當劑量的可卡因,若在高劑量可卡因下,則會由多巴胺受體所取代。總結,本文首次揭露了食慾素在低頻刺激誘發的去增益現象所扮演的角色,同時建議其在場地制約訓練下相關記憶之生理角色。 | zh_TW |
dc.description.abstract | The orexin system consists of two peptides, orexin A and B and two receptors, OX1R and OX2R. It is implicated in learning and memory regulation while controversy remains on its role in modulating hippocampal synaptic plasticity in vivo and in vitro. In our studies, we used extracellular electrophysiological recording to measure the field excitatory postsynaptic potentials (fEPSPs), at the Schaffer collateral-CA1 synapse of mouse hippocampal slices. We also used conditioned place preference (CPP) paradigm to measure the hippocampal associated learning and drug primed preference behavior.
First, we investigated effects of orexin A on two forms of synaptic plasticity, long-term potentiation (LTP) and depotentiation of fEPSPs, at the Schaffer collateral-CA1 synapse of mouse hippocampal slices. Orexin A (≧30 nM) attenuated LTP induced by theta burst stimulation (TBS) in a manner antagonized by an OX1R antagonist (SB334867), but not OX2R antagonist (EMPA). Interestingly, we found orexin A, at 1 pM, co-application of orexin A prevented the induction of depotentiation induced by low frequency stimulation (LFS), namely inducing re-potentiation. This re-potentiation effect of sub-nanomolar orexin A occurred at LFS of 1Hz, but not 2 Hz, and with LTP induced by either TBS or tetanic stimulation. It was significantly antagonized by SB334867, EMPA and TCS1102, selective OX1R, OX2R and dual OXR antagonists, respectively, and prevented by D609, SQ22536 and H89, inhibitors of phospholipase C (PLC), adenylyl cyclase (AC) and protein kinase A (PKA), respectively. LFS-induced depotentiation was antagonized by blockers of NMDA, A1-adenosine and type 1/5 metabotropic glutamate (mGlu1/5) receptors, respectively. However, orexin A (1 pM) did not affect chemical-induced depotentiation by agonists of these receptors. These results suggest that orexin A bidirectionally modulates hippocampal CA1 synaptic plasticity, inhibiting LTP via OX1Rs at moderate concentrations while inducing re-potentiation via OX1Rs and OX2Rs, possibly through PLC and AC-PKA signaling at sub-nanomolar concentrations. Next, we further elucidated the physiological role of our findings on the hippocampal re-potentiation induced by ultra low concentrations of orexin A. Since activating dopamine D1-like receptor (D1-likeR) has been reported to also induce hippocampal re-potentiation and this effect may contribute to the cocaine-CPP behavior, we then examined whether orexin-induced re-potentiation also contribute to cocaine-CPP. We isolated hippocampal slices from the mice going through the CPP test and examined the changes of their hippocampal synaptic plasticity. Indeed, the hippocampal slices in mice that had acquired cocaine-CPP displayed significant hippocampal re-potentiation, as expected. However, we found unexpectedly that needle injection-paired contextual exposures during the CPP task in mice resulted in re-potentiation at CA1 synapses of hippocampal slices, regardless of whether the CPP behavior is expressed or not. Simply exposing the mouse in the CPP apparatus, or giving the mouse consecutive intraperitoneal injections in its home cage or a novel cage did not lead to hippocampal re-potentiation. Besides, this CPP training procedure-induced hippocampal re-potentiation was prevented when mice were pretreated with TCS1102, a dual orexin receptor antagonist. These results suggest that orexin-mediated modulation on hippocampal depotentiation by the training process in the CPP paradigm. Finally, we examined the contribution of endogenous orexins in hippocampal re-potentiation in mice acquiring cocaine-CPP. We found that cocaine-CPP mice at 10 or 20 mg/kg were able to show the same magnitude of CPP and hippocampal re-potentiation. A dual orexin receptor (OXR) antagonist, TCS1102 was used to attenuate the effect of cocaine CPP and the hippocampal re-potentiation in cocaine-CPP mice at moderate dose (10 mg/kg) but not high dose (20 mg/kg). However, dopamine D1-likeR antagonist, SCH23390 was able to attenuate the cocaine-CPP and the hippocampal re-potentiation in cocaine-CPP mice at moderate or high dose. In summary, these results suggest that orexin A can bidirectionally modulate hippocampal CA1 synaptic plasticity; inhibiting LTP via OX1Rs at moderate concentrations while inducing re-potentiation via OX1Rs and OX2Rs, possibly through PLC and AC-PKA signaling at sub-nanomolar concentrations. LFS-induced hippocampal depotentiation is vulnerable to the low level of orexin that can be released upon there is an association between the differential spatial contexts in the CPP apparatus and needle injections in the CPP test, leading to hippocampal re-potentiation. In the other aspect, orexin-mediated hippocampal re-potentiation may also function during the formation of cocaine-CPP. However, this effect of orexins only works at moderate doses of cocaine and will be replaced by dopamine, via D1-likeRs when cocaine is at higher doses. Together, we revealed that orexins can inhibit LFS-induced hippocampal depotentiation to keep hippocampal synaptic transmission remaining potentiated. This modulatory effect on the hippocampal synaptic plasticity may play a role in CPP training-associated memory. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:42:35Z (GMT). No. of bitstreams: 1 ntu-107-D98443002-1.pdf: 5596010 bytes, checksum: b757d3351e6aa90f29f0afa58ad7318e (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 摘要, VIII
Abstract, XI Abbreviation, XV Introduction, 1 1.The hypocretin/orexin system, 1 1.1.Discovery and nomenclature, 1 1.2.Receptors and distributions, 2 1.3.Functions, 4 1.3.1.Arousal and narcolepsy, 4 1.3.2.Metabolic homeostasis, 5 1.3.3.Pain, 7 1.3.4.Reward, 7 1.3.5.Hippocampal learning memory and synaptic plasticity, 9 1.3.5.1.CPP and hippocampal orexins, 12 2.Synaptic Plasticity, 13 2.1.Abuse drug and depotentiation, 13 Aim of study, 15 Materials and Methods, 17 1.The CPP paradigm, 17 2.Saline-conditioning in different contexts, 18 3.Brain slices preparation, 18 4.Electrophysiological recordings, 18 4.1.LTP, 20 4.2.Depotentiation, 20 4.3.Paired-pulse facilitation (PPF), 21 5.Immunofluorescence staining, 21 6.Chemicals, 22 7.Statistical analysis, 24 Results, 25 1.Orexin A induces bidirectional modulation of synaptic plasticity: Inhibiting LTP and preventing depotentiation, 25 1.1.Orexin A decreased TBS-LTP via OX1Rs, 25 1.2.Orexin A prevented depotentiation induced by TBS-LFS (1 Hz) via OX1Rs and OX2Rs, 27 1.3.Sub-nanomolar orexin A did not affect chemical-induced depotentiation of TBS-LTP, 29 1.4.Characterization of the stimulation protocol required for sub-nanomolar orexin A-induced re-potentiation, 31 1.5.Sub-nanomolar orexin A induced re-potentiation via AC-PKA and PLC pathways, 32 1.6.Sub-nanomolar orexin A did not induce significant long-term changes in basal synaptic transmission or two forms of synaptic plasticity in CA1 hippocampal slices, 33 2.Conditioned place preference training prevents hippocampal depotentiation in an orexin-dependent manner, 35 2.1.LFS failed to induce hippocampal depotentiation in both cocaine- and saline-conditioned groups in the CPP paradigm, 35 2.2.Saline or cocaine injections in home-caged mice did not induce re-potentiation, 37 2.3.The injection procedure-paired contextual exposures in the CPP apparatus is required for re-potentiation, 38 2.4.Endogenous orexins are involved in CPP training-induced hippocampal re-potentiation, 40 3.Orexin-mediated restoration of hippocampal synaptic potentiation in mice with cocaine-conditioned place preference, 41 3.1.LFS failed to induce hippocampal depotentiation in vitro in mice with cocaine-CPP, 41 3.2.SB334867, an OX1R antagonist, did not prevent CPP and re-potentiation induced by 20 mg/kg cocaine at both expression and acquisition phases, 42 3.3.TCS1102, an OX1/OX2R antagonist, did not affect CPP and re-potentiation induced by 20 mg/kg cocaine, 44 3.4.TCS1102, an OX1/OX2R antagonist, inhibited CPP and re-potentiation induced by 10 mg/kg cocaine, 45 3.5.SCH23390, a D1-likeR antagonist, prevented CPP and re-potentiation induced by both 10 and 20 mg/kg cocaine, 46 3.6.Co-treated with SCH23390 and TCS1102 prevented the CPP and hippocampal re-potentiation induced by 20 mg/kg cocaine, 48 3.7.Interactions between OXR and D1-likeR ligands in hippocampal re-potentiation, 49 Discussion, 51 1.Orexin A bidirectionally regulates synaptic plasticity, 51 2.Sub-nanomolar orexin A induced re-potentiation of fEPSPs, 51 2.1.An orexin receptor-mediated effect, 51 2.2.Orexin A involvement is specific to electrically-induced, but not chemically-induced, depotentiation, 52 2.3.Frequency-dependence of orexin re-potentiation, 54 2.4.Involvement of PLC and AC-PKA pathways, 55 3.Orexin A inhibited TBS-LTP via OX1R, 56 4.Orexin A did not affect basal synaptic transmission in CA1 hippocampal slices, 57 5.Functional correlates of bi-directional regulation by orexin A on hippocampal synaptic plasticity, 58 6.Conditioned place preference training prevents hippocampal depotentiation in an orexin-dependent manner, 60 7.Orexin-mediated restoration of hippocampal synaptic potentiation in mice with cocaine-conditioned place preference, 64 7.1.Endogenous orexins are involved in the CPP induced by a moderate dose cocaine, 65 7.2.Dopamine D1-likeRs mediate cocaine-CPP, 67 7.3.Contributions of orexin-OX1/OX2R and dopamine-D1-likeR signaling in hippocampal re-potentiation and cocaine-CPP, 68 7.4.The association between hippocampal re-potentiation and cocaine-CPP, 70 Conclusions, 72 References, 74 Tables and Figures, 86 Fig.1.Schematic drawing of coronal and sagittal section through rat brain, summarizing the orexin neuronal system, 86 Fig.2.Orexin A depressed TBS-LTP of fEPSPs via OX1Rs at Schaffer collateral-CA1 synapses in mouse hippocampal slices, 87 Fig.3.Effects of OX1R and OX2R antagonists on TBS-LTP of fEPSPs at Schaffer collateral-CA1 synapses in mouse hippocampal slices, 89 Fig.4.Sub-nanomolar orexin A prevented depotentiation of fEPSPs via OX1Rs and OX2Rs at Schaffer collateral-CA1 synapses in mouse hippocampal slices, 90 Fig.5.Effects of OXR antagonists on TBS-LFS induced depotentiation of fEPSPs at Schaffer collateral-CA1 synapses in mouse hippocampal slices, 93 Fig.6.The role of NMDA, A1-adenosine and mGlu1/5 receptors in TBS-LFS-induced depotentiation and in orexin A-induced re-potentiation, 94 Fig.7.Effects of orexin A on the depotentiation induced by various HFS and LFS protocols, 96 Fig.8.Effects of the AC (SQ22536), PKA (H89) or PLC (D609) antagonist on 1 pM orexin A-induced re-potentiation, 98 Fig.9.Effects of 1 pM orexin A on basal synaptic transmission, paired-pulses ratio and fEPSPs during TBS-LTP or LFS, 100 Fig.10.The effect of 100 nM orexin A on basal synaptic transmission, 101 Fig.11.The effect of 100 nM orexin A on the maintenance phase of TBS-LFS depotentiation, 102 Fig.12.CPP training prevents LFS-induced hippocampal depotentiation in vitro, 103 Fig.13.Home cage pairings with saline or cocaine injections in mice failed to prevent LFS-induced hippocampal depotentiation in vitro, 105 Fig.14.Home cage pairings with saline or cocaine injections in mice did not affect TBS-induced hippocampal LTP in vitro, 107 Fig.15.Novel cage pairing with saline injections or injection-free CPP training did not affect TBS-induced hippocampal LTP in vitro, 108 Fig.16.Novel cage pairing with saline injections or injection-free CPP training failed to prevent LFS-induced hippocampal depotentiation in vitro, 110 Fig.17.Differential exposures in the CPP apparatus in injection-free mice did not induce preference, 112 Fig.18.Pretreatment with TCS1102, a dual orexin receptor antagonist, restored LFS-induced hippocampal de-potentiation in vitro in mice underwent saline-paired CPP training, 113 Fig.19.Pretreatment with TCS1102, a dual orexin receptor antagonist did not affect CPP score in mice underwent saline-paired CPP training, 115 Fig.20.Immunofluorescence staining for OX1Rs and OX2Rs in mouse hippocampal slices, 116 Fig.21.Establishment of cocaine-conditioned preference in mice, 117 Fig.22.TBS-LFS failed to induce hippocampal depotentiation, i.e., inducing re-potentiation, in cocaine-conditioned mice, 118 Fig.23.Pretreatment with SB334867, an orexin receptor 1 antagonist did not affect hippocampal re-potentiation in 20 mg/kg cocaine-conditioned mice, 120 Fig.24.Pretreatment with TCS1102, a dual orexin receptor antagonist did not affect hippocampal re-potentiation in 20 mg/kg cocaine-conditioned mice, 122 Fig.25.Pretreatment with TCS1102, a dual orexin receptor antagonist inhibited hippocampal re-potentiation in 10 mg/kg cocaine-conditioned mice, 124 Fig.26.Pretreatment with SCH23390, a dopamine D1-likeR antagonist inhibited hippocampal re-potentiation in 10 mg/kg and 20 mg/kg cocaine-conditioned mice, 126 Fig.27.Co-treatment with SCH23390 and TCS1102 before conditioning inhibited hippocampal re-potentiation in 20 mg/kg cocaine-conditioned mice, 128 Fig.28.TCS1102 (an OX1R/OX2R antagonist) inhibited SKF38393 (a D1-likeR agonist)-induced re-potentiation and SCH23390 (a D1-likeR antagonist) inhibited orexin A-induced re-potentiation, 130 Fig.29.The potential mechanisms of orexin A-induced or D1-likeR signalings in hippocampal re-potentiation, 132 Table 1: The effects of orexin system in the hippocampal-associated learning behavior models, 133 Table 2: The effects of orexin system in the hippocampal-associated in vivo electrophysiological recording, 135 Table 3: The effects of orexin system in the hippocampal-associated in vitro electrophysiological recording, 136 Table 4: The summary table for results 1.3~1.6, 137 Table 5: the effects of OX1R (SB334867), dual OXR (TCS1102, TCS) or dopamine D1-likeR (SCH23390, SCH) antagonists on the cocaine CPP mice elicited preference or hippocampal depotentiation (DEP) change during acquisition or expression phase, 138 Table 6: The effects of orexin receptor antagonists in cocaine CPP, 139 Bibliography, 140 | |
dc.language.iso | en | |
dc.title | 食慾素在海馬突觸可塑性中的角色及行為呈現 | zh_TW |
dc.title | The role of orexins in hippocampal synaptic plasticity and its behavioral presentation | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 連正章(Cheng-Chang Lien),游一龍(Lung Yu),閔明源(Ming-Yuan Min),黃玲玲(Ling-Ling Hwang),姚皓傑(Hau-Jie Yau) | |
dc.subject.keyword | 食慾素,突觸可塑性,制約場地偏好,海馬迴, | zh_TW |
dc.subject.keyword | Orexin,synaptic plasticity,conditioned place preference,hippocampus, | en |
dc.relation.page | 140 | |
dc.identifier.doi | 10.6342/NTU201800358 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-02-07 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 5.46 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。